President Obama’s fiscal year 2016 budget eliminates all funding for the Centers for Disease Control prostate cancer program. Congress has the power to protect the CDC Prostate Cancer program. We ask for your advocacy to protect this life saving program. Please go to http://malecare.org/cdc There, you will find a sample letter, which you are welcome to copy whole or [...]
It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are [...]
Between 2011 and 2013, the proportion of men diagnosed with intermediate- or high-risk prostate cancer, increased by 3% per year. Thank you members of the United States Preventive Services Task Force for realy blowing it and tapping in the nail into the coffins of American men. In a preliminary study the authors estimate that this [...]
There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]
Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. A study published online in Clinical Cancer Research, indicates that cabazitaxel might be more effective for some men than docetaxel. [...]